Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment. Proceeds from the financing will be used to develop novel T-cell […]
Sonova Holding, providers of hearing aid solutions, has completed the placement of CHF 450 million Bonds governed by Swiss law. Application will be made for the Bonds to be listed on the SIX Swiss Exchange. The Bonds will be issued in two tranches, the first tranche with a duration until 2029 and a coupon of […]
KSA Group has taken another important step on the way to the new green building “Dreiklang”, KSA’s new ecological construction project. The KSA Group was able to raise CHF 120 million on the capital market by issuing its first green bond. The offering, which was developed under the leadership of UBS and with the Basellandschaftliche […]
Private equity firm Astrog has entered into a binding agreement with privately owned industrial group International Chemical Investors Group (“ICIG”) whereby Astorg will acquire CordenPharma, a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with highly differentiated capabilities in Active Pharmaceutical Ingredients, Excipients, and Drug Products, from ICIG. As part of the transaction, the founders […]
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital Management, with participation from Omega Funds. Homburger advised CDR-Life in the transaction. The Homburger team was led by partner […]
Groupe Bruxelles Lambert (GBL) acquires a majority stake in Sanoptis, a network of ophthalmology clinics across Germany and Switzerland, from the private equity Telemos Capital. GBL is committing up to EUR 750 million in equity for this transaction with the aim to accelerate the company’s growth in partnership with its management and doctors. In this sense, as part of the transaction, the […]
Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from the firm’s Ridgeline Discovery Engine in Basel, Switzerland. Cimeio’s initial focus is on a novel approach to hematopoietic stem cell […]
Bär & Karrer advised on the sale of Brust-Zentrum Zurich, a Swiss medical center specialised in the diagnosis and professional treatment of the breast. The owners of Brust-Zentrum Zurich have entered a strategic alliance with Affidea, a european provider of advanced diagnostic imaging, cancer therapies and outpatient services. With this partnership, Affidea Switzerland expands in […]
DentaCore, a privately held corporation specialising in acquisitions, investments and consolidation in the fragmented dental medicine sector, has acquired Cera-Tech, an innovative dental manufacturer. Headquartered in Switzerland, DentaCore focuses on the integration of outstanding practices, clinics and laboratories. The consistent realization of synergy effects and process optimisation leads to improved services and lower costs for […]
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a publicly traded special purpose acquisition company. The business combination was unanimously approved by Helix’s board of directors and was approved […]
